Skip to main content
LUSHANG FREDA PHARMACEUTICAL CO.,LTD. logo

LUSHANG FREDA PHARMACEUTICAL CO.,LTD. — Investor Relations & Filings

Ticker · 600223 ISIN · CNE000001147 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,828 across all filing types
Latest filing 2024-08-23 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600223

About LUSHANG FREDA PHARMACEUTICAL CO.,LTD.

http://www.lshfreda.com/

Lushang Freda Pharmaceutical Co., Ltd. specializes in the research, development, and manufacturing of pharmaceutical products, health supplements, and high-end cosmetics. The company is recognized as a global leader in the production of sodium hyaluronate (hyaluronic acid), utilizing advanced fermentation technology to supply raw materials for medical, food, and cosmetic applications. Its product portfolio spans several therapeutic areas, including ophthalmology, orthopedics, and dermatology, with a significant focus on medical aesthetics and functional skincare. By integrating biotechnology with industrial-scale production, the company maintains a comprehensive supply chain that supports both its proprietary brands and international B2B partnerships. Key operations involve the synthesis of bioactive substances and the formulation of specialized treatments designed to improve skin health and joint mobility.

Recent filings

Filing Released Lang Actions
鲁商福瑞达医药股份有限公司关于2024年第二季度主要经营数据的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement disclosing the main operating data for the second quarter of 2024, including production volume, sales volume, revenue, and price changes of products and raw materials. It is titled as an "announcement" and contains no detailed financial statements or comprehensive financial analysis typical of an Interim/Quarterly Report (IR). The document length is short (1395 characters), and it primarily provides summary operational data rather than full financial results. It does not fit the description of an earnings release (ER) which usually highlights key financial results, nor is it a full quarterly report with financial statements. It is a regulatory announcement of quarterly operating data, which aligns best with the Regulatory Filings (RNS) category as a general regulatory announcement that does not fit other specific categories.
2024-08-23 Chinese
鲁商福瑞达医药股份有限公司关于会计政策变更的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from the board of directors regarding a change in accounting policies effective from January 1, 2024, based on new accounting standards issued by the Ministry of Finance. It details the nature of the accounting policy change, its impact, and the board's approval. The document is relatively short (1435 characters) and does not contain financial statements or detailed financial data. It is an official announcement about accounting policy changes rather than a full audit report or annual report. Therefore, it fits best under Regulatory Filings (RNS), which covers miscellaneous regulatory announcements that do not fit other categories.
2024-08-23 Chinese
鲁商福瑞达医药股份有限公司2024年半年度利润分配预案公告
Notice of Dividend Amount Classification · 95% confidence The document is titled as a "2024 Half-Year Profit Distribution Plan Announcement" by the company. It details the proposed cash dividend per share, the total dividend amount, and the decision-making process including board and supervisory committee approvals. It explicitly states that the plan is subject to shareholder meeting approval. The document is an announcement of a dividend distribution plan rather than the actual dividend payment notice or a full financial report. It is relatively short (1088 characters) and focuses on the dividend distribution proposal. Therefore, it fits best under the category of Notice of Dividend Amount (DIV), as it announces the dividend distribution plan and related details to shareholders.
2024-08-23 Chinese
鲁商福瑞达医药股份有限公司2024年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '2024 年半年度报告' which translates to '2024 Semi-Annual Report'. It contains detailed financial data, management discussion and analysis, company business segments, accounting data, and financial indicators for the period January 1, 2024 to June 30, 2024. The document is comprehensive, with 216 pages and about 15,000 characters, indicating it is a full report rather than a brief announcement. It includes sections such as management discussion and analysis, financial statements, company overview, and risk disclosures, which are typical components of an Interim / Quarterly Report. The document explicitly states it is a half-year report and includes actual financial data and analysis, not just references or certifications. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2024
2024-08-23 Chinese
鲁商福瑞达医药股份有限公司关于山东省商业集团财务有限公司的风险持续评估报告
Audit Report / Information Classification · 95% confidence The document is a detailed risk assessment report by 鲁商福瑞达医药股份有限公司 regarding 山东省商业集团财务有限公司. It includes extensive information on internal controls, risk management, financial metrics as of June 30, 2024, and compliance with regulatory requirements. The content focuses on risk evaluation, internal control systems, and financial safety rather than presenting a full annual or interim financial report. It is not a certification or a brief announcement but a substantive risk assessment report. This aligns best with the category 'Audit Report / Information (AR)', which covers standalone audit reports, applied accounting principles, and internal risk assessments excluding full annual reports. The document length (4229 characters) is sufficient to contain detailed substantive content, not just an announcement or certification. Therefore, the classification is AR with high confidence. H1 2024
2024-08-23 Chinese
鲁商福瑞达医药股份有限公司2024年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a '2024年半年度报告摘要' which translates to '2024 Semi-Annual Report Summary'. It contains detailed financial data for the half-year period, including net profit, revenue, asset totals, shareholder information, and profit distribution plans. The document explicitly states it is a summary of the half-year report and advises investors to read the full report on the official website. The content includes substantive financial data and analysis for a period shorter than a full fiscal year, consistent with an Interim / Quarterly Report. The document length is 3051 characters, which is relatively short but contains actual financial data, not just an announcement or certification. Therefore, it should be classified as an Interim / Quarterly Report (IR). H1 2024
2024-08-23 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.